Related Experiment Video

Updated: Jul 8, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines

Yasuyuki Deguchi1, Shinya Kimura, Eishi Ashihara

  • 1Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara-cho Shogoin Sakyo-ku, Kyoto 606-8507, Japan.

Leukemia Research
|January 15, 2008
PubMed

Insights

This study compared four tyrosine kinase inhibitors, finding that nilotinib and INNO-406 effectively target BCR-ABL mutations resistant to dasatinib, offering potential for specific leukemia treatments.

Area of Science:

  • Oncology and Pharmacology
  • Molecular Biology
  • Drug Discovery

Background:

  • Tyrosine kinase inhibitors (TKIs) are crucial in treating chronic myeloid leukemia (CML).
  • BCR-ABL is a key driver mutation in CML.
  • SRC family kinases (SFKs) can contribute to TKI resistance.

Purpose of the Study:

  • To compare the efficacy and selectivity of imatinib, dasatinib, nilotinib, and INNO-406 against BCR-ABL and SFKs.
  • To evaluate the potential of these TKIs in overcoming specific BCR-ABL mutations.
  • To assess their utility in P-glycoprotein overexpressing leukemic cells.

Main Methods:

  • In vitro assessment of growth-inhibitory effects.
  • Analysis of inhibition profiles against BCR-ABL and SRC family kinases (SFKs).
  • Evaluation against specific BCR-ABL mutations (T315A, F317L, F317V).

Main Results:

  • Dasatinib showed high potency against BCR-ABL but low selectivity over SFKs.
  • Nilotinib demonstrated high specificity for ABL and potential for P-glycoprotein overexpressing cells.
  • INNO-406 had intermediate BCR-ABL affinity and selectively inhibited LCK and LYN SFKs.
  • Both nilotinib and INNO-406 potently inhibited dasatinib-resistant BCR-ABL mutations.

Conclusions:

  • Nilotinib and INNO-406 are effective against key dasatinib-resistant BCR-ABL mutations.
  • Nilotinib's specificity may benefit patients with P-glycoprotein overexpressing leukemia.
  • These findings support the development of targeted therapies for resistant CML.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...